Skip to main content
S&P 5007,568.92+0.36%DOW51,786.72-0.38%NASDAQ25,372.01+0.83%BTC$76,850.00-0.36%ETH$2,261.28+0.13%GOLD$3,968.20+0.71%OIL$95.60-0.51%
Smart Investors Daily
SID Premium
EL

NASDAQ · ELDN

Eledon Pharmaceuticals, Inc.

Healthcare · Biotechnology

$2.62

Up+$0.00 (+0.00%)

Updated Nov 4, 2026, 9:28 AM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
102.42M
P/E ratio
-1.65
Dividend yield
0.00%
52-week range
$2.11 – $4.49
Volume
403.81K
Avg. volume
2.2M

Price performance · ELDN

ELDN price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

ELDN closed at $2.62 after 21 trading sessions, up 6.94% for the selected period.

Last close
$2.62
Period change
+6.94%
Period low
$2.13
Period high
$3.04
Daily close
View OHLC price history
ELDN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$2.62$2.75$2.58$2.62403.81K
Nov 2, 2026$2.81$2.864$2.55$2.62672.69K
Oct 30, 2026$2.99$3.04$2.745$2.771.27M
Oct 29, 2026$2.77$3.219$2.73$3.043.11M
Oct 28, 2026$2.40$2.81$2.3716$2.762.08M
Oct 27, 2026$2.22$2.44$2.22$2.41935.29K
Oct 26, 2026$2.33$2.37$2.20$2.21654.7K
Oct 23, 2026$2.29$2.35$2.195$2.30420.03K
Oct 22, 2026$2.26$2.32$2.225$2.30526.7K
Oct 21, 2026$2.25$2.33$2.24$2.26625.62K
Oct 20, 2026$2.16$2.33$2.1398$2.255740.34K
Oct 19, 2026$2.15$2.24$2.11$2.161.05M
Oct 16, 2026$2.27$2.419$2.13$2.13803.25K
Oct 15, 2026$2.25$2.349$2.2101$2.27582.32K
Oct 14, 2026$2.31$2.36$2.22$2.25987.5K
Oct 13, 2026$2.49$2.49$2.32$2.341.17M
Oct 12, 2026$2.50$2.58$2.425$2.44440.6K
Oct 9, 2026$2.42$2.5555$2.42$2.48818.75K
Oct 8, 2026$2.40$2.44$2.36$2.42834.62K
Oct 7, 2026$2.42$2.48$2.39$2.42583.6K
Oct 6, 2026$2.53$2.56$2.42$2.45830.33K

Latest ELDN news

The latest Smart Investors Daily articles mentioning ELDN.

Stock researchCompany · Overview

ELDN research

Overview

Company profile and research snapshot.

Company profile

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$9.00
Implied upside
—
Analysts
—
ELDN recent ratings
DateFirmRatingTarget
Jul 21, 2026Rodman & RenshawBuy—
Nov 18, 2025GuggenheimBuy—
Sep 2, 2025HC Wainwright & Co.Buy—
Jul 25, 2025Craig-HallumBuy—
Nov 20, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 26, 2026

Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual Meeting

Tegoprubart-treated patients demonstrated a mean improvement on the total MTSOSD-59R symptom occurrence scale at 12 months while tacrolimus-treated patients experienced a mean worsening of symptom occurrence Statistically significant improvement on the KDQOL-SF Symptoms and Problems Scale among tegoprubart-treated patients through 12 months following kidney transplantation versus tacrolimus Results further validate the differentiated clinical profile of tegoprubart and potential to transform sta

Yahoo · Oct 5, 2026

Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting

IRVINE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation will be featured at the upcoming American Society of Nephrology Kidney Week 2026 Annual Meeting taking place in Denver, CO, from October 21-25, 2026. The oral presentation will highlight patient-reported outcomes from the Phase 2 BESTOW trial evaluating tegoprubart for the prevention of rejection in kidney transplantation. Details of the presentation are b

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By